Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Medical Research Council |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00040690 |
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have Burkitt's lymphoma or Burkitt's leukemia.
Condition | Intervention | Phase |
---|---|---|
Leukemia Lymphoma |
Drug: cyclophosphamide Drug: cytarabine Drug: doxorubicin hydrochloride Drug: etoposide Drug: filgrastim Drug: ifosfamide Drug: leucovorin calcium Drug: methotrexate Drug: vincristine sulfate Procedure: radiation therapy |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | A Clinicopathological Study In Burkitts's And Burkitt-Like Non-Hodgkin's Lymphoma |
Estimated Enrollment: | 120 |
Study Start Date: | November 2008 |
Ages Eligible for Study: | 16 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of diffuse B-cell lymphoma in a nodal or an extranodal site
Diagnosis of bone marrow replacement/leukemia comprising mature B-cell lymphoma
Patients in the low-risk group must meet at least 3 of the following criteria:
Patients in the high-risk group must meet at least 2 of the following criteria:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
United Kingdom, England | |
Medical Research Council Clinical Trials Unit | |
London, England, United Kingdom, NW1 2DA |
Study Chair: | Simon Clawson | Medical Research Council |
Study ID Numbers: | CDR0000069374, MRC-LY10, EU-20117 |
Study First Received: | July 8, 2002 |
Last Updated: | November 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00040690 |
Health Authority: | United States: Federal Government |
untreated adult acute lymphoblastic leukemia L3 adult acute lymphoblastic leukemia stage I adult Burkitt lymphoma stage III adult Burkitt lymphoma |
stage IV adult Burkitt lymphoma contiguous stage II adult Burkitt lymphoma noncontiguous stage II adult Burkitt lymphoma |
Leukemia, Lymphoid Lymphoma, small cleaved-cell, diffuse Leucovorin Cyclophosphamide Etoposide phosphate Acute lymphoblastic leukemia, adult Lymphoma, B-Cell Leukemia Burkitt's lymphoma Methotrexate Epstein-Barr Virus Infections Etoposide Lymphoma Cytarabine Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Immunoproliferative Disorders Vincristine Doxorubicin Herpesviridae Infections Folic Acid Virus Diseases Calcium, Dietary Lymphatic Diseases Ifosfamide Burkitt Lymphoma B-cell lymphomas DNA Virus Infections Lymphoproliferative Disorders Lymphoma, Non-Hodgkin Isophosphamide mustard |
Antimetabolites Anti-Infective Agents Antimetabolites, Antineoplastic Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Tumor Virus Infections Reproductive Control Agents Antibiotics, Antineoplastic Neoplasms, Experimental Therapeutic Uses Vitamins Abortifacient Agents Micronutrients |
Dermatologic Agents Alkylating Agents Nucleic Acid Synthesis Inhibitors Neoplasms by Histologic Type Vitamin B Complex Immune System Diseases Growth Substances Mitosis Modulators Enzyme Inhibitors Antimitotic Agents Folic Acid Antagonists Abortifacient Agents, Nonsteroidal Immunosuppressive Agents Antiviral Agents Pharmacologic Actions |